Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 11:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 83 matching trials from the live ClinicalTrials.gov search.
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

NCT02160990
Conditions
Obesity
Interventions
Exenatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Type 2 Diabetes
Interventions
placebo, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
40
States / cities
Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
19 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Type 2 Diabetes
Interventions
Placebo, Exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
Interventions
BYDUREON, Placebo
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Exendin-4 SC, Placebo SC
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Diabetes Mellitus
Interventions
Exantide with Dapagliflozin, Exentide, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
76
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscumbia, Alabama + 61 more
Conditions
Healthy Adult Premenopausal Female Volunteers
Interventions
ITCA 650 20/60 mcg/day, ITCA placebo, ITCA placebo, ITCA 650 20/60 mcg/day
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Conditions
Evaluate Ketogenic Stress
Interventions
Exenatide/Exenatide extended release, Dapagliflozin, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Williamsville, New York
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide (GSK716155) or exenatide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
158
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 142 more
Conditions
Type 2 Diabetes
Interventions
HM11260C, liraglutide, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 74 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
CA, California
Conditions
Diabetes Mellitus
Interventions
placebo, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
5
States / cities
Temple, Arizona • Colorado Springs, Colorado • Honolulu, Hawaii + 2 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
23
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 19 more
Conditions
Diabetes Type 2
Interventions
Exenatide once weekly suspension, Sitagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 50 more
Conditions
Type 2 Diabetes
Interventions
ITCA 650, ITCA placebo
Drug · Other
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
121
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 102 more
Completed Phase 3 Interventional Results available

Effect on Weight Loss of Exenatide Versus Placebo

NCT00375492
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Peoria, Arizona • Jacksonville, Florida • Orlando, Florida + 7 more
Conditions
Type 2 Diabetes
Interventions
exenatide, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • Portland, Oregon
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
100
States / cities
Anniston, Alabama • Birmingham, Alabama • Montgomery, Alabama + 82 more
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Placebo 0.01 mL, Placebo 0.02 mL, Placebo 0.03 mL, Placebo 0.04 mL, AC2993 2.5 mcg, AC2993 5.0 mcg, AC2993 7.5 mcg, AC2993 10.0 mcg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
33
States / cities
Birmingham, Alabama • Anaheim, California • Bellflower, California + 28 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Exenatide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide - Exenatide - Placebo, Exenatide - Placebo - Exenatide, Placebo - Exenatide - Exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 16 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Little Rock, Arkansas • San Diego, California • Denver, Colorado + 2 more
Conditions
Weight Loss, Obesity
Interventions
Byetta (exenatide), Weight loss, Metabolic Chamber, Placebo
Drug · Behavioral · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Type 2 Diabetes
Interventions
Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Chula Vista, California • Orlando, Florida
Conditions
Cocaine Use Disorder
Interventions
Exenatide, Placebo
Drug
Lead sponsor
Christopher D. Verrico
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas